

Anna Ferrari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5756830/publications.pdf>

Version: 2024-02-01

52
papers

1,093
citations

393982

19
h-index

414034

32
g-index

52
all docs

52
docs citations

52
times ranked

2608
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 795-811.	2.4	6
2	Identification of a novel RAB31Pâ€HMGA2 fusion transcript in an adult head and neck rhabdomyosarcoma. <i>Oral Diseases</i> , 2022, 28, 2052-2054.	1.5	7
3	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1356-1362.	0.6	2
4	Rearrangements of ATP5Lâ€KMT2A in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 192, e139-e144.	1.2	3
5	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. <i>Biomedicines</i> , 2021, 9, 388.	1.4	6
6	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. <i>Leukemia</i> , 2021, 35, 2813-2826.	3.3	15
7	Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684396.	1.3	6
8	Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway. <i>Blood Cancer Journal</i> , 2021, 11, 7.	2.8	3
9	Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11564.	1.8	21
10	Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9724.	1.8	4
11	Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1999-2002.	1.0	0
12	Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2019, 11, 1654.	1.7	18
13	Identification of Two <i>DNMT3A</i> Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	3
14	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1951.	1.7	17
15	Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. <i>Cancer</i> , 2019, 125, 712-725.	2.0	49
16	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018, 32, 1609-1620.	3.3	80
17	RALE051: a novel established cell line of sporadic Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1252-1255.	0.6	0
18	Targeting CDK6 and BCL2 Exploits the â€œMYB Addictionâ€ of Ph+ Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2018, 78, 1097-1109.	0.4	19

#	ARTICLE	IF	CITATIONS
19	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 99.	6.9	35
20	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. <i>Blood</i> , 2018, 132, 5284-5284.	0.6	0
21	A new bi-layered scaffold for osteochondral tissue regeneration: In vitro and in vivo preclinical investigations. <i>Materials Science and Engineering C</i> , 2017, 70, 101-111.	3.8	64
22	Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. <i>Leukemia</i> , 2017, , .	3.3	3
23	Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 53377-53391.	0.8	34
24	Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data. <i>BMC Bioinformatics</i> , 2016, 17, 341.	1.2	103
25	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. <i>Oncotarget</i> , 2016, 7, 12951-12961.	0.8	28
26	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 125.	6.9	28
27	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 24.	2.0	4
28	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 6553-6569.	0.8	58
29	Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. <i>Leukemia Research</i> , 2014, 38, 581-585.	0.4	20
30	Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. <i>Pharmacogenomics Journal</i> , 2013, 13, 335-341.	0.9	28
31	Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome. <i>Hematology Reports</i> , 2013, 5, 7.	0.3	7
32	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. <i>Blood</i> , 2013, 122, 2622-2622.	0.6	11
33	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harboring T315I Mutation: The Bologna Experience. <i>Blood</i> , 2013, 122, 3911-3911.	0.6	0
34	Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2012, 2, e61-e61.	2.8	8
35	IKAROS Deletions Dictate a Unique Gene Expression Signature in Patients with Adult B-Cell Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2012, 7, e40934.	1.1	73
36	Cytogenetic and Molecular Predictors of Outcome in Acute Lymphocytic Leukemia: Recent Developments. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 133-143.	1.2	42

#	ARTICLE	IF	CITATIONS
37	In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012, 120, 1496-1496.	0.6	3
38	Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2012, 120, 2522-2522.	0.6	1
39	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. <i>Blood</i> , 2012, 120, 2601-2601.	0.6	4
40	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. <i>Blood</i> , 2012, 120, 1749-1749.	0.6	0
41	Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2012, 120, 2497-2497.	0.6	0
42	IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. <i>Leukemia</i> , 2011, 25, 178-181.	3.3	27
43	A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2011, 35, 1052-1059.	0.4	74
44	Alterations Impair Prognosis in Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia Patients. <i>Clinical Cancer Research</i> , 2011, 17, 7413-7423.	3.2	62
45	Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. <i>Leukemia</i> , 2010, 24, 66-73.	3.3	26
46	The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. <i>Haematologica</i> , 2010, 95, 1683-1690.	1.7	51
47	Efficacy and Feasibility of Nelarabine Salvage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen. <i>Blood</i> , 2010, 116, 4335-4335.	0.6	1
48	The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2010, 116, 3136-3136.	0.6	0
49	Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 7049-7049.	0.8	0
50	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. <i>Haematologica</i> , 2008, 93, 1814-1821.	1.7	39
51	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type B) on Chromosome 12p12.1 (12p12.1) on Behalf of the GIMEMA ALL Working Party. <i>Blood</i> , 2008, 112, 428-428.	0.6	0
52	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. <i>Blood</i> , 2008, 112, 1497-1497.	0.6	0